Catalyzing Transcriptomics Research in Cardiovascular Disease: The CardioRNA COST Action CA17129.
2019
Аутори:
Gomes, Clarissa Pedrosa da CÁgg, Bence
Andova, Andrejaana
Arslan, Serdal
Baker, Andrew
Barteková, Monika
Beis, Dimitris
Betsou, Fay
Wettinger, Stephanie Bezzina
Bugarski, Branko
Condorelli, Gianluigi
Silva, Gustavo José Justo da
Danilin, Sabrina
de Gonzalo-Calvo, David
Buil, Alfonso
Carmo-Fonseca, Maria
Enguita, Francisco J
Felekkis, Kyriacos
Ferdinandy, Peter
Gyöngyösi, Mariann
Hackl, Matthias
Karaduzovic-Hadziabdic, Kanita
Hellemans, Jan
Heymans, Stephane
Hlavackova, Markéta
Hoydal, Morten Andre
Janković, Aleksandra
Jusic, Amela
Kardassis, Dimitris
Kerkelä, Risto
Kuster, Gabriela M
Lakkisto, Päivi
Leszek, Przemyslaw
Lustrek, Mitja
Maegdefessel, Lars
Martelli, Fabio
Novella, Susana
O'Brien, Timothy
Papaneophytou, Christos
Pedrazzini, Thierry
Pinet, Florence
Popescu, Octavian
Potočnjak, Ines
Robinson, Emma
Sasson, Shlomo
Scholz, Markus
Simionescu, Maya
Stoll, Monika
Varga, Zoltan V
Vinciguerra, Manlio
Xuereb, Angela
Yilmaz, Mehmet Birhan
Emanueli, Costanza
Devaux, Yvan
on behalf of the EU-CardioRNA COST Action (CA17129)
Тип документа:
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт:
Cardiovascular disease (CVD) remains the leading cause of death worldwide and, despite continuous advances, better diagnostic and prognostic tools, as well as therapy, are needed. The human transcriptome, which is the set of all RNA produced in a cell, is much more complex than previously thought and the lack of dialogue between researchers and industrials and consensus on guidelines to generate data make it harder to compare and reproduce results. This European Cooperation in Science and Technology (COST) Action aims to accelerate the understanding of transcriptomics in CVD and further the translation of experimental data into usable applications to improve personalized medicine in this field by creating an interdisciplinary network. It aims to provide opportunities for collaboration between stakeholders from complementary backgrounds, allowing the functions of different RNAs and their interactions to be more rapidly deciphered in the cardiovascular context for translation into the clinic, thus fostering personalized medicine and meeting a current public health challenge. Thus, this Action will advance studies on cardiovascular transcriptomics, generate innovative projects, and consolidate the leadership of European research groups in the field.COST (European Cooperation in Science and Technology) is a funding organization for research and innovation networks (www.cost.eu).
Кључне речи:
Best practices and guidelines; Cardiovascular disease; Personalized medicine; Transcriptomics; Translational researchИзвор:
Non-Coding RNA, 2019, 5, 2, 31-Финансирање / пројекти:
- COST (European Cooperation in Science and Technology) Action EU-CardioRNA (CA17129)
DOI: 10.3390/ncrna5020031
PubMed: 30934986
WoS: 000474931400001
Scopus: 2-s2.0-85069910260
URI
https://www.mdpi.com/2311-553X/5/2/31http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6630366
https://radar.ibiss.bg.ac.rs/handle/123456789/3443